Dr. Michael E. Dever

Internal Medicine
3226 Downs Cove Rd, 
Windermere, FL 
3226 Downs Cove Rd, 
Windermere, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Dever is a primary care provider, practicing in Internal Medicine in Windermere, Florida. His top area of expertise is Pericarditis.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

3226 Downs Cove Rd, Windermere, FL 34786

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia
Enrollment Status: Terminated
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Ferric Carboxymaltose
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.
Enrollment Status: Terminated
Publish Date: April 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
View 7 Less Clinical Trials

2 Total Publications

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.
Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination.
Journal: Infectious diseases and therapy
Published: November 13, 2023
Similar Doctors
Expertise in
32
conditions
Dr. Dinesh K. Khanna
Internal Medicine
Expertise in
32
conditions
Dr. Dinesh K. Khanna
Internal Medicine
1580 Santa Barbara Blvd, Suite C, 
The Villages, FL 
 (41.2 miles away)
352-259-2159
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Dinesh Khanna is a primary care provider, practicing in Internal Medicine in The Villages, Florida. Dr. Khanna is highly rated in 32 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Interstitial Lung Disease, Acute Interstitial Pneumonia, and Lung Transplant. Dr. Khanna is currently accepting new patients.

Expertise in
44
conditions
Dr. Jaime C. Gonzalez
Internal Medicine
Expertise in
44
conditions
Dr. Jaime C. Gonzalez
Internal Medicine

Orlando Family Physicians LLC

265 W Hwy 50, 
Clermont, FL 
 (15.2 miles away)
352-394-5535
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jaime Gonzalez is a primary care provider, practicing in Internal Medicine in Clermont, Florida. Dr. Gonzalez is highly rated in 44 conditions, according to our data. His top areas of expertise are Hypertensive Heart Disease, Pediatric Myocarditis, Necrosis, and Enlarged Liver. Dr. Gonzalez is currently accepting new patients.

Expertise in
74
conditions
Dr. Mark G. Brooks
Internal Medicine
Expertise in
74
conditions
Dr. Mark G. Brooks
Internal Medicine

Mark G Brooks M D P A

10000 W Colonial Dr, Suite 187, 
Ocoee, FL 
 (3.2 miles away)
407-578-6610
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Brooks is a primary care provider, practicing in Internal Medicine in Ocoee, Florida. Dr. Brooks is highly rated in 74 conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Heart Murmurs, Hypertension, and Glucocorticoid-Remediable Aldosteronism. Dr. Brooks is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dever's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile